Fredun Pharmaceuticals Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Fredun Pharmaceuticals Ltd is ₹ 2464 as of 06 May 15:30 . The P/E Ratio of Fredun Pharmaceuticals Ltd changed from 16 on March 2025 to 16 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Fredun Pharmaceuticals Ltd changed from ₹ 315.67 crore on March 2025 to ₹ 315.67 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 160.92 crore as compare to the Sep '25 revenue of ₹ 145.29 crore. This represent the growth of 10.76% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The ebitda of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 22.33 crore. This represent the growth of 17.96% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The net profit of Fredun Pharmaceuticals Ltd changed from ₹ 13.74 crore to ₹ 10.48 crore over 5 quarters. This represents a CAGR of -19.48% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The Dividend Payout of Fredun Pharmaceuticals Ltd changed from 13.9 % on March 2021 to 1.59 % on March 2025 . This represents a CAGR of -35.18% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Fredun Pharmaceuticals Ltd

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94.
The Company was promoted by Nariman Medhora and Daulat N Medhora.
The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations.
Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy.
The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Fredun Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Fredun Pharmaceuticals Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Fredun Pharmaceuticals Ltd is 1,358 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,069 Cr

What are the key factors driving the stock performance of Fredun Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Fredun Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fredun Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 6, 2026, the Fredun Pharmaceuticals Ltd stock price is INR ₹2464.55. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2424.3.

How do dividend payouts of Fredun Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Fredun Pharmaceuticals Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.